Reduced postprandial glucose excursions [2]
Demonstrated across randomised trials in type 1 and type 2 diabetes, through combined gastric-emptying delay and glucagon suppression — an effect prandial insulin alone does not achieve.
PrecisePep/Peptide Library/Pramlintide
Metabolic & Adipose Regulation
Pramlintide
Symlin® · pramlintide acetate · amylin analogue
The only approved amylin analogue — the drug that proved beta-cell replacement needs two hormones, not one, and the reason every cagrilintide claim has a safety precedent to answer to.
00 Overview
Beta cells secrete two hormones, not one. Amylin is co-secreted with insulin in roughly a 1:100 molar ratio, and in diabetes both are lost together — insulin deficiency has always been the headline, but amylin deficiency happens at the same time and was not addressed by any therapy until pramlintide.
Native amylin cannot be used as a drug: it is the archetypal amyloidogenic peptide, aggregating into the islet amyloid deposits characteristic of type 2 diabetes. Pramlintide substitutes three prolines to block fibril formation while retaining receptor activity — the same problem cagrilintide solves with acylation.[1]
Approved in 2005 for both type 1 and type 2 diabetes as a mealtime adjunct to insulin, it slows gastric emptying, suppresses inappropriate postprandial glucagon and increases satiety. It flattens post-meal glucose excursions in a way prandial insulin alone does not, and produces modest weight loss rather than the weight gain insulin causes. It has never been widely used, largely because it means additional mealtime injections and demands careful insulin dose reduction.
The boxed warning is the whole story
Pramlintide carries a boxed warning for severe insulin-induced hypoglycaemia, typically within three hours of injection. It is used only alongside insulin, and initiating it requires reducing prandial insulin — the label specifies halving it. Adding an amylin analogue to unchanged insulin is the error the warning exists to prevent, and it is the precedent anyone reasoning about cagrilintide should have in mind.
// Mechanism of action
Amylin receptor agonism. Amylin receptors are calcitonin receptors dimerised with receptor activity-modifying proteins. Agonism in the area postrema produces satiation and slows gastric emptying — meal-termination signalling anatomically distinct from the GLP-1 route.
Postprandial glucagon suppression. In diabetes, glucagon is inappropriately elevated after meals, adding hepatic glucose output to the dietary load. Pramlintide suppresses this, which is a substantial part of its effect on post-meal excursions.
Delayed gastric emptying. Slows the rate at which carbohydrate reaches the small intestine, flattening the glucose curve. This is also why it must be injected immediately before meals and why it alters absorption of concurrent oral drugs.
Anti-amyloidogenic substitutions. Three proline substitutions from the rat amylin sequence prevent the beta-sheet stacking that makes human amylin form fibrils, without abolishing receptor activity.
The dual-hormone argument. Insulin alone replaces half of what the beta cell used to do. Pramlintide is the only approved attempt to replace the other half, which is a conceptually elegant proposition that clinical practice has largely not adopted.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
HbA1c reduction with weight loss rather than gain [2]
Modest HbA1c improvement accompanied by modest weight loss — notable in a class where the alternative adjunct, more insulin, causes weight gain.
Reduced prandial insulin requirement [3]
Adding pramlintide typically allows mealtime insulin to be reduced, which is both a benefit and the source of the boxed warning if the reduction is not made.
Approved in both type 1 and type 2 diabetes [3]
One of very few agents indicated in type 1 diabetes beyond insulin itself — a genuinely unusual position.
Proof of concept for the amylin class [1]
Pramlintide established that amylin agonism is clinically useful, which is the foundation the cagrilintide and CagriSema programmes are built on.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Fine-tuned postprandial control for advanced users
The occasional community rationale — targeting post-meal excursions specifically rather than overall glycaemia. Coherent, and it requires the insulin management that makes it a clinical rather than self-directed decision.
Weight management outside diabetes
The satiety and gastric-emptying effects are real, and the amylin class is being developed for obesity through cagrilintide. Pramlintide itself is short-acting and requires mealtime injections, making it impractical for that purpose.
Restoring the dual-hormone feedback loop
Conceptually attractive and the framing the drug was developed under. Clinical uptake has been limited, which says something about how the trade-off is judged in practice.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Rarely sought in community settings
Short half-life, mealtime injections and mandatory insulin adjustment make it unattractive next to weekly GLP-1 agonists. Community interest is minimal.
Nausea is the limiting factor
Reported as prominent, particularly during titration — consistent with central melanocortin-adjacent satiety signalling.
Injection burden
A separate injection before every meal, on top of insulin, is the practical reason most people stop.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Boxed warning: severe insulin-induced hypoglycaemia [3]
Typically within three hours of injection. The label requires reducing prandial insulin — generally by half — at initiation, with glucose monitoring during titration. This is the defining safety consideration.
Nausea and vomiting [2]
The most common adverse effects, dose-dependent and concentrated during titration, and the leading cause of discontinuation.
Contraindicated in gastroparesis and hypoglycaemia unawareness [3]
Labelled contraindications. A drug that further delays gastric emptying is inappropriate in established gastroparesis, and one that increases hypoglycaemia risk is inappropriate where warning symptoms are already absent.
Altered absorption of oral medication [3]
Delayed gastric emptying alters absorption of concurrent oral drugs. The label advises administering agents requiring rapid absorption at least an hour before, or two hours after, pramlintide.
Immunogenicity [2]
Anti-drug antibodies form in a proportion of users, as for other non-human-sequence peptide analogues.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The precedent for every amylin analogue
Cagrilintide has no boxed warning because it has no label. The hypoglycaemia risk of amylin agonism alongside insulin is a class property, and pramlintide is where it was characterised.
Compounded gastroparesis risk in combination
Amylin and GLP-1 agonism both delay gastric emptying. Stacking them stacks that effect, including any associated anaesthesia aspiration risk.
Never appropriate without insulin
Pramlintide is indicated only as an adjunct to insulin. Using it standalone for appetite effects discards the context the safety data was generated in.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Nausea, frequently limiting
The dominant complaint.
Hypoglycaemia when insulin was not reduced
Exactly the error the boxed warning describes.
Injection-site reactions
Reported at typical rates.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Type 2 diabetes: 60 mcg before major meals, to 120 mcg [3]
Started at 60 mcg immediately before major meals, increased to 120 mcg after three to seven days if nausea has not occurred. Prandial insulin is reduced by 50% at initiation.
Type 1 diabetes: 15 mcg, titrated to 60 mcg [3]
Lower starting dose with 15 mcg increments as tolerated, again with prandial insulin halved at initiation.
Separate injection from insulin [3]
Pramlintide and insulin must not be mixed in the same syringe — they are formulated at different pH and mixing alters both.
| Population | Starting dose | Target | Insulin adjustment |
|---|---|---|---|
| Type 2 diabetes | 60 mcg before major meals | 120 mcg | Reduce prandial insulin 50% |
| Type 1 diabetes | 15 mcg before major meals | 30–60 mcg | Reduce prandial insulin 50% |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Insulin reduction is not optional
The single most important operational point. The boxed warning exists because people add it without reducing insulin.
Titrate against nausea
The labelled schedule advances only if nausea has not occurred, which makes tolerability rather than glucose the pacing variable during initiation.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Little contemporary community practice
Not widely used outside clinical settings, and community dosing discussion is correspondingly sparse.
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Insulin — the only approved context [3]
Pramlintide is indicated solely as a mealtime adjunct to insulin. The combination is the drug, and the boxed warning describes what happens when the insulin side is not adjusted.
The amylin plus incretin concept [1]
Pramlintide established amylin agonism clinically; the cagrilintide programme extended it into a long-acting analogue paired with a GLP-1 agonist. The lineage runs directly from this drug.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Serious interaction: insulin and any glucose-lowering agent
The boxed warning covers insulin specifically. Adding a GLP-1 agonist on top compounds it further.
Oral drug absorption
Delayed gastric emptying alters absorption of concurrent oral medication, with labelled timing advice.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Rarely stacked
The mealtime injection burden keeps it out of most community protocols.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Labelled initiation protocol [3]
Insulin reduction, stepwise titration paced by nausea, glucose monitoring during titration, and separate injection from insulin.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Glucose monitoring during titration is the protocol
As with insulin itself, the regimen is titrated against measured glucose rather than a schedule.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Not part of any documented protocol here
Neither the Gold Standard Protocol nor the 15-Compound Matrix includes it.
05b Condition-specific interest
Pramlintide is the clinical precedent for the entire amylin class, and its label is the reason anyone combining an amylin analogue with insulin should be paying attention.
No approval, no trial
Approved as an adjunct to mealtime insulin in type 1 and type 2 diabetes, with a boxed warning for severe insulin-induced hypoglycaemia. The label requires prandial insulin to be reduced — typically halved — when pramlintide is started. That instruction is the most important thing on this page.
Actionable — the precedent that matters
The boxed warning — and what it means for cagrilintide
Pathophysiology
Amylin is co-secreted with insulin and is deficient alongside it in diabetes. Replacing it slows gastric emptying, suppresses postprandial glucagon and increases satiety — all of which lower post-meal glucose.
Mechanistic rationale
Because it lowers post-meal glucose by mechanisms independent of insulin, the existing insulin dose becomes an overdose. Severe hypoglycaemia within three hours of injection is the labelled risk, and the mitigation is halving prandial insulin at initiation. Cagrilintide is a long-acting amylin analogue in the same class, and nobody adding it to an insulin regimen from a research vial is halving anything.
Community reports
The pramlintide precedent is almost never cited in community discussion of amylin analogues, which is the gap this entry exists to close.
Components carrying the argument: Amylin receptor — insulin-independent glucose lowering
Study — approved
Type 1 diabetes — a rare adjunct with a real rationale
Pathophysiology
In type 1 diabetes both insulin and amylin are lost, because both come from the beta cell. Insulin replacement addresses half of that.
Mechanistic rationale
Pramlintide is one of very few agents approved as an adjunct to insulin in type 1 diabetes, and the rationale is unusually clean: it replaces the other hormone that was lost. Postprandial glucose excursions and glucagon suppression both improve.
Community reports
Uptake has been limited by the injection burden — it is a separate injection at every meal — and by nausea.
Components carrying the argument: Amylin replacement
Study — modest here, larger in the newer analogues
Obesity and weight
Pathophysiology
Amylin signalling contributes to meal termination and satiety through hindbrain pathways distinct from GLP-1.
Mechanistic rationale
Weight loss with pramlintide is real and modest. The class became interesting again when long-acting analogues arrived — cagrilintide alone and in CagriSema — because a weekly agent with a larger effect changes the calculation. Pramlintide is the proof of concept rather than the product.
Community reports
Used off-label for weight, where the mealtime injection schedule is the limiting factor.
Components carrying the argument: Amylin-mediated satiety
Study
Nausea and the titration requirement
Pathophysiology
Delayed gastric emptying is both a mechanism of benefit and a mechanism of nausea.
Mechanistic rationale
Nausea is common, dose-related and the main reason for discontinuation, which is why the label specifies gradual titration. It also delays absorption of orally administered drugs, so anything requiring rapid absorption should be taken at least an hour before or two hours after.
Community reports
Nausea dominates the reporting, as across every gastric-emptying-delaying agent in this library.
Components carrying the argument: Gastric emptying delay
| Question | Position |
|---|---|
| Approved for | Adjunct to mealtime insulin, type 1 and type 2 |
| Boxed warning | Severe insulin-induced hypoglycaemia |
| Required at initiation | Halve prandial insulin |
| Relevance to cagrilintide | Same class; nobody halves anything from a research vial |
| Weight effect | Modest — the long-acting analogues are the story |
| Main tolerability limit | Nausea; requires gradual titration |
What actually has evidence for these conditions
For type 1 diabetes: insulin with structured education, continuous glucose monitoring and hybrid closed-loop systems where available, which have improved both control and hypoglycaemia rates substantially.
For type 2 diabetes: metformin, SGLT2 inhibitors and GLP-1 agonists with outcome data, and insulin when beta-cell function requires it — with the dose reduced whenever another glucose-lowering agent is added.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied as a ready-to-use solution in pens. Research-grade pramlintide is uncommon. Note that it must never be mixed in a syringe with insulin — the two are formulated at different pH.
Storage
Unopened: refrigerated 2–8 °C. In use: refrigerated or room temperature for a defined period, typically 30 days. Do not freeze.
Common vial sizes
Licensed: 1000 mcg/mL pens delivering 15–120 mcg doses.
Stability notes
As an amylin-family peptide it is engineered specifically against aggregation, but visible haze or particulate still indicates a product that should not be used.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Discontinued in the United States. Pramlintide acetate injection (Symlin) has been withdrawn from the US market, with the discontinuation recorded in late 2025. It remains the clinical precedent for the amylin class and the reason the boxed warning on this page matters for cagrilintide and CagriSema — but it is no longer an available option, which changes what this page is for. It is now history rather than a treatment.
FDA approved since 2005 as Symlin, for type 1 and type 2 diabetes as a mealtime adjunct to insulin. Prescription medicine with a boxed warning for severe insulin-induced hypoglycaemia.
Commercial availability has narrowed over time as the class moved toward long-acting agents, and it was never widely prescribed relative to its conceptual interest.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: Symlin discontinued in the US, recorded late 2025. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
Insulin and agents affecting glucose metabolism are addressed under WADA S4. Treat as prohibited absent a therapeutic use exemption.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- PubMed: pramlintide and amylin analogue pharmacology, including anti-amyloidogenic design (live query)Database or literature search
- PubMed: pramlintide randomised trials in type 1 and type 2 diabetes (live query)Database or literature search
- FDA label: pramlintide (Symlin) — boxed warning, contraindications and dosingRegulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.